Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacokinetic/Pharmacodynamic (PK/PD) and Safety Evaluation of Oseltamivir [Tamiflu] in the Treatment of Infants 0 to <12 Months of Age With Confirmed Flu Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* infants \</=12 months of age~* laboratory confirmed diagnosis of influenza within 96 hours prior to first dose~* influenza symptoms for \</=96 hours prior to first dose~Exclusion Criteria:~* preterm infants less than 40 weeks (corrected for gestational age)~* weight less than 5th percentile for age (corrected for gestational age)~* concurrent gastrointestinal conditions that preclude enteric absorption of the drug~* bronchopulmonary dysplasia/chronic lung disease on assisted ventilation at time of enrollment~* active or uncontrolled respiratory, cardiac, hepatic, CNS or renal disease at baseline~* symptomatic inborn errors of metabolism

- Gender: ALL
- Minimum Age: None
- Maximum Age: 12 Months
- Healthy Volunteers: f

Study Arms:
- Oseltamivir 3 mg (Type: EXPERIMENTAL): infants 3 to \<12 months
- Oseltamivir 2.5 mg (Type: EXPERIMENTAL): infants 1 to \<3 months of age
- Oseltamivir 2 mg (Type: EXPERIMENTAL): infants 0 to 30 days (post natal) of age

Based on this trial design, predict the completion outcome and termination type (if applicable).